QNRX

Quoin Pharmaceuticals, Ltd. NASDAQ Listed Aug 1, 2016

Healthcare ·Biotechnology ·US · quoinpharma.com

$4.65

+0.65% vs $4.62

Mkt Cap $9.3M

52w Low $4.10 1.5% of range 52w High $41.80

50d MA $5.46 200d MA $9.40

P/E (TTM) 0.0x

EV/EBITDA —

P/B 0.4x

Debt/Equity 0.0x

ROE -120.5%

P/FCF -0.0x

RSI (14) 43.70

ATR (14) $0.47

Beta 1.82

50d MA $5.46

200d MA $9.40

Avg Volume 30.6K

Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.

SIC Code

2834

CIK (SEC)

1671502

Phone

703 980 4182

42127 Pleasant Forest Court · Ashburn, VA 20148-7349 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 26, 2026	AMC	-6.42	-14.80	-130.5%	7.57	-2.1%	-15.3%	-2.0%	+5.1%	-8.2%	+15.8%	—
Nov 6, 2025	AMC	-6.36	-6.71	-5.5%	8.57	-0.9%	+5.1%	-9.7%	+41.4%	+5.0%	+11.0%	—
Aug 7, 2025	AMC	-6.83	-6.28	+8.1%	6.91	+1.2%	+3.5%	-1.4%	+1.8%	+0.0%	+1.7%	—
May 13, 2025	AMC	-3.85	-6.50	-68.8%	6.36	+38.8%	+20.3%	+0.7%	+0.0%	+3.8%	+6.0%	—
Mar 13, 2025	AMC	-0.50	-12.24	-2348.0%	10.32	+0.0%	+3.1%	+0.4%	-3.4%	+1.7%	-3.3%	—
Nov 7, 2024	AMC	-15.38	-16.43	-6.8%	24.25	+1.0%	-3.3%	-4.5%	-3.1%	-0.1%	-1.9%	—
Aug 8, 2024	AMC	-26.22	-13.64	+48.0%	18.34	-6.5%	-5.3%	+7.5%	-2.6%	-7.5%	+4.2%	—
May 9, 2024	AMC	-0.76	-38.81	-5006.6%	27.83	-0.6%	-2.8%	+2.0%	-1.4%	-0.3%	+0.0%	—
Mar 13, 2024	AMC	-82.87	-72.73	+12.2%	40.60	-3.4%	-13.8%	-4.3%	-4.9%	-2.2%	+1.1%	—
Nov 8, 2023	AMC	-83.92	-68.18	+18.8%	154.88	+7.1%	-8.3%	-4.7%	+1.8%	+7.9%	+0.0%	—
Aug 2, 2023	AMC	-2.82	-74.48	-2541.1%	246.05	+1.7%	+6.3%	-10.2%	-8.8%	-3.9%	+3.2%	—
May 8, 2023	AMC	-109.13	-142.71	-30.8%	238.56	-3.5%	-14.1%	-1.0%	-0.6%	+1.7%	-0.2%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 15	Maxim Group	Maintains	Buy → Buy	—	$35.00	$36.05	+3.0%	-4.3%	-4.9%	-2.2%	+1.1%	+0.0%
Sep 7	Alliance Global Partners	Maintains	Buy → Buy	—	$1394.40	$1663.20	+19.3%	+17.8%	-6.9%	+2.2%	+14.5%	-7.7%
May 6	Ladenburg Thalmann	Maintains	Buy → Buy	—	$4247.25	$4830.00	+13.7%	-2.3%	-17.6%	-4.0%	-8.5%	-2.1%
Jan 7	Maxim Group	Maintains	Buy → Buy	—	$9135.00	$10132.50	+10.9%	+19.5%	-11.1%	+3.8%	-3.6%	-10.3%
Dec 15	JMP Securities	Maintains	Market Outperform → Outperform	—	$16695.00	$26722.50	+60.1%	-12.6%	-13.7%	-10.8%	-13.6%	+15.7%

Institutional (13F) — Top 15 All ↗

#	Manager	Shares	Value	Chg	Period
1	Dauntless Investment Group, Llc	196,592	$1M	New	Mar 2026
2	Velan Capital Investment Management Lp	84,849	$560K	New	Mar 2026
3	Woodline Partners Lp	79,582	$525K	—	Mar 2026
4	Millennium Management	76,247	$503K	Added	Mar 2026
5	Aberdeen Group Plc	75,000	$495K	—	Mar 2026
6	Soleus Capital Management, L.p.	72,730	$480K	Added	Mar 2026
7	Centiva Capital, Lp	60,000	$396K	Added	Mar 2026
8	Stonepine Capital Management, Llc	53,460	$353K	Reduced	Mar 2026
9	Aigh Capital Management Llc	51,000	$337K	Added	Mar 2026
10	Citadel Advisors Llc	32,519	$215K	New	Mar 2026
11	Morgan Stanley	6,000	$87K	New	Dec 2025
12	Ubs Group Ag	2,512	$17K	Added	Mar 2026
13	Gamma Investing Llc	1,720	$11K	Reduced	Mar 2026
14	Barclays Plc	1,300	$9K	New	Mar 2026
15	Royal Bank Of Canada	11	—	New	Mar 2026

Mutual Funds / ETFs (N-PORT) — Top 0 All ↗

No N-PORT holders found.

Data updated apr 26, 2026 9:33pm · Source: financialmodelingprep.com